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Using data from a national wound-specific electronic medical record (WoundExpert,
Net Health, Pittsburgh, PA), we compared the effectiveness of a bilayered living
cellular construct (BLCC) and an acellular porcine small intestine submucosa collagen
dressing (SIS) for the treatment of venous leg ulcer. Data from 1,489 patients with
1,801 refractory venous leg ulcers (as defined by failure to have >40% reduction in size
in the 4 weeks prior to treatment) with surface areas between 1 and 150 cm2 in size,
treated between July 2009 and July 2012 at 158 wound care facilities across the US
were analyzed. Patient baseline demographics and wound characteristics were com-
parable between groups. Kaplan-Meier–derived estimates of wound closure for BLCC
(1,451 wounds) was significantly greater (p = 0.01, log-rank test) by weeks 12 (31%
vs. 26%), 24 (50% vs. 41%), and 36 (61% vs. 46%), respectively, compared with SIS
(350 wounds). BLCC treatment reduced the median time to wound closure by 44%,
achieving healing 19 weeks sooner (24 vs. 43 weeks, p = 0.01, log-rank test). Treat-
ment with BLCC increased the probability of healing by 29% compared with porcine
SIS dressing (hazard ratio = 1.29 [95% confidence interval 1.06, 1.56], p = 0.01).
Venous leg ulcers (VLUs) are the most common type of
chronic leg wound. These often painful wounds represent the
majority of lower extremity ulcerations1–4 and have a lifetime
prevalence that has been estimated at 1% of adults,5–8 with rates
even higher among the elderly (1.69% prevalence, annually).9
VLUs also pose a significant financial burden to US payers, at
an estimated annual direct medical cost of up to $18bn.10
In addition to local wound care and infection control, the
standard treatment for VLUs is compression therapy. However,
with standard care alone, research has shown that up to 75% of
patients fail to achieve healing in a timely fashion.11 For these
hard-to-heal VLUs, treatment algorithms have recommended
the use of evidence-based advanced technologies to modulate
and accelerate the healing process.12–14
A bilayered living cellular construct (BLCC; Apligraf,
Organogenesis Inc., Canton, MA) is at present the only
product approved by the FDA for the treatment of VLUs.
BLCC is comprised of human neonatal keratinocytes and
fibroblasts in an extracellular matrix (bovine collagen and
other extracellular matrix proteins) and has been in clinical
use for the treatment of VLUs since 1998. In order to gain
FDA approval for the treatment of VLUs, BLCC was evalu-
ated in a pivotal trial where it showed that when used in
conjunction with compression therapy, BLCC significantly
increased the percentage of patients healed by 6 months and
reduced the median time to wound closure.15
Porcine small intestine submucosa (SIS; Oasis,
Healthpoint, Fort Worth, TX) is an acellular wound dressing
that has been cleared by the FDA for the management of
VLUs. The efficacy of SIS has been evaluated in a leg ulcer
clinical trial, where application of SIS with compression
therapy was found to significantly increase the percent of
wounds healed by 3 months compared with compression
therapy alone.16
Although the efficacy of these products has been evaluated
in randomized controlled clinical trials, the comparative
effectiveness for treating VLUs in real-world settings has not
been investigated. Although the 2009 Affordable Care Act
has provided $1.1bn for comparative effectiveness research
BLCC Bilayered living cellular construct
CER Comparative effectiveness research
EMR Electronic medical record
HBO2 Hyperbaric oxygen therapy
HFDS Human fibroblast-derived dermal substitute
HIPAA Health Insurance Portability and Accountability Act
NPWT Negative pressure wound therapy
RCT Randomized controlled trial
SIS Small intestine submucosa
VLU Venous leg ulcer
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(CER), few comparative effectiveness studies have ever been
performed in the wound care field.17,18 Effective treatment is
the extent to which an intervention produces its intended
effect in routine care conditions (real-world situations),
whereas efficacious treatment provides positive results in con-
trolled, highly constrained conditions that are optimal for
obtaining favorable results in randomized controlled trials
(RCTs).18,19 Thus, it is important to determine if efficacy can
be translated to routine practice settings (effectiveness) to
support evidence-based practice.
The purpose of this study was to investigate the compara-
tive effectiveness of BLCC to SIS for the treatment of VLUs
in real-world settings using data over a 3-year period from a
large wound care–specific electronic medical record (EMR)
database (WoundExpert, Net Health, Pittsburgh, PA) that is
utilized by approximately 20,000 physicians in over 1,000
wound care facilities across the US.
METHODS
Study design
This study is a retrospective analysis to compare the effec-
tiveness of BLCC and SIS for the treatment of VLUs using
de-identified EMRs from wound care facilities across the US
in a 3-year period. The primary analyses were frequency of
wound closure evaluated up to 36 months and median time
to wound closure. Wound areas (cm2) were calculated from
wound measurements of length and width. The final visit
denoting VLU closure was not always recorded; thus, wound
closure was defined as an ulcer achieving an area between 0
and 0.25 cm2.
Patients
Patients eligible for inclusion were those documented as
receiving at least one treatment of either BLCC or SIS on a
venous ulcer (partial or full thickness) with the location coded
as ankle, lower leg, shin, pretibial, or calf. Included baseline
wound areas were 1–150 cm2 with an ulcer duration of longer
than 1 month prior to first treatment with BLCC or SIS. To
assure analyses were restricted to refractory VLUs, wounds
needed to have closed no more than 40% within the 4 weeks
prior to first treatment with BLCC or SIS.
Wounds without baseline or follow-up area measurements
were excluded as well as those where the date of BLCC or SIS
treatment was unknown. Wounds were also excluded if they
received either SIS or human fibroblast-derived dermal sub-
stitute (HFDS; Dermagraft, Shire Regenerative Medicine,
San Diego, CA) on or within 28 days of the first treatment
with BLCC or, alternatively, if they received BLCC or HFDS
on or within 28 days of the first treatment with SIS. Censoring
occurred for nonhealed wounds at their last visit with an area
measurement. Patients were also censored at the visit where
an alternate product was applied (either BLCC, SIS, or
HFDS). Wounds treated with the same product >183 days
after the prior application were censored at the visit where the
subsequent application occurred. Other concurrent treatments
such as hyperbaric oxygen (HBO2) or negative pressure
wound therapy (NPWT) were allowed.
Data collection
Data were obtained from the WoundExpert EMR, which was
de-identified consistent with the terms and conditions of the
Health Insurance Portability and Accountability Act of 1996
(HIPAA).
Net Health provided all treatment records for any patient
receiving at least one application of BLCC or SIS between
July 2009 and July 2012 from the 158 centers with contracted
agreements for the transfer of de-identified data for research
purposes.
Treatment records included patient baseline demographics
including age (years, ≤89 per HIPAA), gender, race, wound
location, wound size and duration, and wound-specific infor-
mation recorded at each visit including area measurements
and treatments.
Statistical analysis
Descriptive data are expressed as mean (standard deviation)
and median for continuous variables and n (%) for categorical
variables. The level of p < 0.05 was established for the
purpose of defining statistical significance. Baseline charac-
teristics were compared using two-sample t tests and Fisher’s
exact two-tailed tests. The primary analyses comparing
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Figure 1. Patient and wound data screening for entry into
analyses. Bilayered living cellular construct (BLCC), Apligraf;
small intestine submucosa (SIS), Oasis; human fibroblast-
derived dermal substitute (HFDS), Dermagraft.
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incidence of and median time to wound closure were
determined by Kaplan-Meier analysis with two-tailed log-
rank test. The last observation was carried forward for
missing data. The hazard ratio along with its 95% confidence
interval (CI) and p-value is based on a Cox proportional
hazards regression model with one term for treatment
group.
RESULTS
The patient screening flow chart is shown in Figure 1. In 158
centers over a 3-year period, a total of 3702 VLUs (2,428
patients) received BLCC treatment, and 1,143 VLUs (838
patients) received SIS treatment. From these, 1,451 wounds
(1,187 patients) and 350 wounds (302 patients) treated with
BLCC and SIS respectively met the eligibility requirements
for inclusion in the analysis.
There were no significant differences in baseline patient
demographics and wound characteristics between the two
treatment groups, except for number of wounds per patient
(Tables 1 and 2). The majority of patients was women
(54.9%), Caucasian (73.1%), and the median age was 71
years. At the first treatment application, the median wound
area was 7.5 cm2 in the BLCC group and 6.0 cm2 in the SIS
group, with the majority of ulcers being full thickness
(87.7%). The median wound duration was 5.3 and 7.1 months
in the BLCC and SIS groups, respectively.
As shown in Table 3, the average number of treatment
applications received by patients in the BLCC group was
significantly lower than SIS-treated patients (p < 0.0001). A
significantly higher percentage of BLCC-treated patients
received a single application compared with SIS (p < 0.0001).
For patients receiving multiple applications, the median inter-
val between applications was significantly longer in the
BLCC group (p < 0.0001).
Treatment with HBO2 or NPWT in the 28 days prior to
initial BLCC or SIS application or concurrently was uncom-
mon and comparable between treatment groups (Table 3).
Kaplan-Meier analysis of available data up to 36 months
showed BLCC treatment significantly improved the median
time to VLU wound closure by 44%, achieving the endpoint
19 weeks sooner than the SIS-treated patients (24 weeks for
BLCC vs. 43 weeks for SIS, p = 0.01) (Figure 2). The esti-
mated incidence of wound closure for BLCC compared with
SIS was significantly improved by weeks 12 (31% vs. 26%),
24 (50% vs. 41%), and 36 (61% vs. 46%), respectively
(p = 0.01) (Figure 3). BLCC treatment significantly increased
the probability of wound healing by 29% compared with
SIS treatment (hazard ratio = 1.29 [95% CI: 1.06, 1.56],
p = 0.01).





(n = 302) p-Value*
Age (years), n 1,185 300 0.655
Mean ± SD 69.5 ± 13.9 69.1 ± 14.4
Median 71.0 71.0
Gender, n (%) 0.217
Male 551 (47.2) 129 (43.1)
Female 616 (52.8) 170 (56.9)
Race, n (%) 0.501
Caucasian 571 (73.7) 148 (72.5)
Black 103 (13.3) 33 (16.2)
Other 101 (13.0) 23 (11.3)
BMI (kg/m2), n 859 209 0.460
Mean ± SD 32.8 ± 11.1 32.1 ± 11.0
Median 30.5 29.8
Number of wounds per patient, n 1,187 302 0.041
Mean ± SD 1.22 ± 0.6 1.16 ± 0.5
Median 1.0 1.0
Single/multiple wounds per patient, n (%) 0.189
Single wound 988 (83.2) 261 (86.4)
Multiple wounds 199 (16.8) 41 (13.6)
*For BMI, the p-value is from the Wilcoxon rank-sum test testing for a difference in distribution between treatments. For other
categorical variables, the p-value is from a two-tailed Fisher’s exact test testing for a difference in proportions between
treatments. For continuous variables, the p-value is from a two-tailed, two-sample t test, testing for a difference in means
between treatments.
BLCC, Apligraf; SIS, Oasis. BLCC, bilayered living cellular construct; BMI, body mass index; SD, standard deviation; SIS, small
intestine submucosa.
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This retrospective analysis of EMR data from US wound care
facilities showed that use of BLCC was more effective than
SIS for the treatment of VLUs in the study population which
was selected to represent a real-world setting. BLCC-treated
wounds were found to have a significantly higher incidence of
wound closure and reduced the median time to achieve wound
closure by 44%. This study represents the largest real-world
comparative effectiveness analysis of products used in the
treatment of VLUs.
Efficacy reflects the degree to which an intervention pro-
duces the expected result under carefully controlled condi-
tions. RCTs provide the best method for establishing efficacy
and are considered to have high “internal validity” because of
randomization, careful selection of participants, and standard-
ized treatment protocols, all of which are intended to maxi-
mize the possibility of observing a treatment effect, if it
exists.18,20,21 Although RCTs are considered level 1 evidence
and the “gold standard” in determining if a product can actu-
ally work, there may be limitations in the generalizability or
“external validity” of data generated.22 The strict criteria for
patient inclusion (which may exclude “higher-risk” patients),
rigorous monitoring, and adherence to treatment protocols
may create a potentially artificial environment that may not be
entirely representative of the typical patient population or the
routine practice conditions where these products are uti-
lized.18,20 Evaluating real-world effectiveness is therefore
important as it does not narrowly select patient populations
but evaluates an intervention as it is typically utilized in prac-
tice without intense efforts to standardize its use. Results of
these pragmatic trials are often considered to be more widely
applicable and complementary to RCTs as they evaluate an
intervention in ordinary settings and in broader populations.23
CER is defined by the pragmatic aim of informing a spe-
cific health-care decision through the explicit comparison of
clinically credible, alternative interventions in a representa-
tive study population. The Institute of Medicine issued a
report in 2009 to set priorities for national CER that would
support better decision making about interventions in health
care.20 The report highlighted the need to perform compari-
sons of interventions among patients in typical patient care
settings and to focus resources on the most promising
approaches.24 However, despite this call for more comparative
research, there remains a paucity of head-to-head comparative
data available to guide clinicians.
In effectiveness studies, performance is often reduced in
less homogeneous populations treated outside of expert clini-
cal research centers and in a less rigorous fashion; thus, it is
important to determine if efficacy can be translated to routine
practice settings. Although direct comparisons between RCTs
and the results presented here cannot be made because of
differences in study design and patient populations, we found
the incidence of complete wound closure for the 146 BLCC-
treated patients in the pivotal RCT was 63% at week 2415
compared with 50% in this analysis. In the SIS RCT, the





(n = 302) p-Value*
Wound area (cm2), n 1,451 350 0.590
Mean ± SD 16.2 ± 22.1 15.5 ± 23.6
Median 7.5 6.0
Full/partial thickness, n (%) 0.638
Full thickness 1,172 (88.2) 292 (87.2)
Partial thickness 157 (11.8) 43 (12.8)
Wound duration (months)†, n 1,091 262 0.355
Mean ± SD 17.0 ± 56.6 20.1 ± 48.5
Median 5.3 7.1
Wound location, n (%) 0.479
Ankle 386 (26.6) 101 (28.9)
Lower leg 957 (66.0) 231 (66.0)
Shin 8 (0.6) 0 (0.0)
Calf 68 (4.7) 11 (3.1)
Pretibial 32 (2.2) 7 (2.0)
Lateral/medial, n (%) 0.165
Lateral 471 (47.5) 98 (42.2)
Medial 520 (52.5) 134 (57.8)
*For categorical variables, the p-value is from a two-tailed Fisher’s exact test testing for a difference in proportions between
treatments. For continuous variables, the p-value is from a two-tailed, two sample t test, testing for a difference in means
between treatments.
†Wound duration was reported in days and was converted to months according to the following: 30 days = 1 month.
BLCC, Apligraf; SIS, Oasis. BLCC, bilayered living cellular construct; SD, standard deviation; SIS, small intestine submucosa.
Marston et al. Effectiveness of BLCC vs. SIS in VLU
Wound Rep Reg (2014) 22 334–340 © 2014 The Authors. Wound Repair and Regeneration published by Wiley Periodicals, Inc. on behalf of
Wound Healing Society
337
incidence of closure at week 12 was 55% in the 62 treated
patients16 compared with 26% in this analysis.
VLUs are estimated to affect as many as 2.5 million US
patients and have considerable negative effects on quality of
life.4,25–27 The economic burden imposed by VLUs on the
health-care system and payers was highlighted in a recent
analysis of more than 81,000 VLU patients published by Rice
et al. which estimated the direct costs to be up to $18bn
annually.10 A subset of this analysis performed on the Medi-
care VLU patients receiving skin substitutes during the cor-





(n = 302) p-Value*
Number of treatment applications, n 1,451 350 <0.0001
Mean ± SD 2.3 ± 1.5 3.8 ± 3.2
Median 2.0 3.0
Single/multiple applications, n (% patients) <0.0001
Single 582 (40.1) 100 (28.6)
Multiple 869 (59.9) 250 (71.4)
Interval between applications (days), n 869 250 <0.0001
Mean ± SD 31.7 ± 24.1 12.6 ± 12.3
Median 24.5 8.5
Number of debridements at or within 28 days
prior to day 0†, n
0.846
1,155 236
Mean ± SD 2.6 ± 1.3 2.6 ± 1.5
Median 3.0 3.0
Other treatments, n (% patients)
HBO2
Day −28 to <day 0† 28 (1.9%) 5 (1.4%) 0.660
Day 0 to last follow-up visit 33 (2.3%) 8 (2.3%) 1.000
NPWT
Day −28 to <day 0 25 (1.7%) 5 (1.4%) 0.820
Day 0 to last follow-up visit 30 (2.1%) 8 (2.3%) 0.836
*For categorical variables, the p-value is from a two-tailed Fisher’s exact test testing for a difference in proportions between
treatments. For continuous variables, the p-value is from a two-tailed, two sample t test, testing for a difference in means between
treatments.
†Day 0 defined as first application visit.
BLCC, Apligraf; SIS, Oasis. BLCC, bilayered living cellular construct; HBO2, hyperbaric oxygen therapy; NPWT, negative pressure
wound therapy; SD, standard deviation; SIS, small intestine submucosa.
24 weeks
43 weeks





Figure 2. Median time to wound closure from Kaplan-Meier
analysis of all available data up to 3 years. Bilayered living
cellular construct (BLCC), Apligraf; small intestine submucosa






























Figure 3. Estimated incidence of wound closure from Kaplan-
Meier analysis of all available data up to 3 years. Bilayered
living cellular construct (BLCC), Apligraf; small intestine sub-
mucosa (SIS), Oasis. *p-Value from a two-sided log-rank test.
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responding time period found that the total health-care costs
were $537 per week higher for patients who were still incur-
ring VLU-related costs (“nonhealed” ulcers) compared with
those no longer incurring VLU-related costs (“healed”
ulcers). Of this amount, $377 per week was for selected
services considered directly related to VLU treatment.28
Therefore the 19-week difference in median healing time
(week 24 vs. 43) in the current analysis should result in
substantial cost savings (between $7,000 and $10,000 addi-
tional costs). This estimate likely understates the overall
burden as it does not include 20% of costs not covered by
Medicare. Moreover, it does not factor in important indirect
costs such as those associated with quality of life or lost
productivity because of patient and caregiver missed work.
Although BLCC costs more per applied unit than SIS, cost
savings might be realized with BLCC treatment given fewer
and less frequent applications received by patients in this
analysis and the considerable costs associated with having a
wound remain open an additional 19 weeks. Further specifics
on relative costs would require a database with more detailed
information than was available for this analysis.
We recognize that this study, like all retrospective analyses,
is “noisier” than a typical prospective randomized controlled
study. A limitation of this study is that EMR databases often
are not developed specifically for research purposes, and lack
of control on the quantity of specific information exists as
well as difficulties in standardizing the information collected.
Although certain fields within the WoundExpert EMR were
reliably and consistently completed (such as wound measure-
ments), information regarding the type of secondary dressing
or compression therapy were found to be recorded less con-
sistently and often entered as “free text,” making reliable
analyses difficult. Completion of baseline demographic infor-
mation fields such as medical history, prior surgical interven-
tions, or concomitant medications varied across centers,
making certain subgroup analyses difficult. Additionally, the
reporting of safety-related outcomes, adverse events, or ulcer
recurrence was not possible as this information was not reli-
ably captured within the database. Finally, given the lack of
randomization, there is a possibility of bias in selection of
patients for BLCC or SIS at the centers involved in patient
care. However, given the number of wounds and centers pro-
viding information for the analysis, it is less likely that a
uniform bias was present affecting study results.
There are also many advantages offered by the
WoundExpert EMR. Electronic health-care databases are
widely used to assess the comparative effectiveness of thera-
peutics in real-world settings29 and offer the benefit of provid-
ing large study populations and longer observation periods.30
WoundExpert provides a robust source for data as it is specifi-
cally designed for the wound care field and is used nationwide
by centers treating the relevant population and utilizing the
products of interest. This study analyzed data collected over a
3-year period from a large number of patients treated in facili-
ties across the US.
It is also important to note that in this analysis, we sought to
investigate outcomes in refractory “hard-to-heal” VLUs and
excluded wounds that had reduced in size >40% in the prior 4
weeks, a threshold which has showed high negative predictive
value (i.e., identifies wounds that will not achieve closure in a
timely fashion).31 This 4-week prognostic milestone has been
adopted across the field of wound care to identify patients who
may benefit from intervention with advanced therapy, yet
interestingly, few previous studies have employed protocols
that apply this criteria for inclusion. These results therefore
provide valuable information to guide treatment decisions for
patients with these recalcitrant wounds.
In conclusion, these real-world data showed that BLCC,
compared with SIS, significantly improved the probability,
speed, and the incidence of wound closure in VLUs.
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